LLY · 10-Q · 2026Q2 · Full report
Operating Expense Trends
ELI LILLY & Co · 2026-08-05 · Importance 52 · Surprise 22 · From source text
Research and development expense increased 14% to $3,819 million in the second quarter and 21% to $7,329 million for the first six months of 2026. R&D growth reflected continued investment in Lilly’s early- and late-stage development portfolio. Marketing, selling, and administrative expense rose 25% to $3,430 million in the quarter and 22% to $6,364 million for the six months. The SG&A increase was primarily driven by promotional efforts supporting ongoing and planned product launches.
Key facts
- Marketing, selling, and administrative expenses for the three months ended June 30, 2026: $3,430 million, an increase of 25 percent versus prior year. source
- Research and development expenses for the three months ended June 30, 2026: $3,819 million, an increase of 14 percent versus prior year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -3.0% | Marketing, selling, and administrative expenses for the three months ended June 30, 2026: $3,430 million, an increase of 25 percent versus… |
| operating_income | negative | realized | -2.1% | Research and development expenses for the three months ended June 30, 2026: $3,819 million, an increase of 14 percent versus prior year. |